Latest news with #JenniferBath
National Post
5 days ago
- Business
- National Post
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
Article content AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a company operating at the convergence of TechBio and biological intelligence, today announced that it has received formal notification from The Nasdaq Stock Market LLC ('Nasdaq') confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. Article content The notice, dated July 11, 2025, stated that for the 10 consecutive business days from June 26, 2025, through July 10, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed. Article content Article content 'This compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native AI,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We're building the digital infrastructure that connects biological complexity with real-world impact – enabling new possibilities in therapeutic development and beyond. The recent momentum in our share price is a strong signal of support for that vision.' Article content Through its proprietary LENS ai™ platform powered by HYFT ® technology, ImmunoPrecise is reimagining how biological data can be modeled and deployed at scale. The LENS ai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere. Article content Our integrated framework enables unprecedented zero-shot discovery scenarios where LENS ai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. This unique bio-native AI approach captures functional meaning rather than structural patterns, enabling new capabilities across R&D from drug and vaccine discovery to systems biology and positioning IPA at the frontier of TechBio innovation. Article content About ImmunoPrecise Antibodies Ltd. Article content ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT ® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Article content Forward-Looking Statements Article content This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the Company's strategic direction, the Company's future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. Article content Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in AI and biotechnology; and other risks inherent to the Company's industry and business model. Article content Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Article content Article content Article content Article content Article content Article content Article content
Business Wire
5 days ago
- Business
- Business Wire
ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), a company operating at the convergence of TechBio and biological intelligence, today announced that it has received formal notification from The Nasdaq Stock Market LLC ('Nasdaq') confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), concerning the minimum bid price requirement. We're building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond. The notice, dated July 11, 2025, stated that for the 10 consecutive business days from June 26, 2025, through July 10, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed. 'This compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native AI,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We're building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond. The recent momentum in our share price is a strong signal of support for that vision.' Through its proprietary LENS ai™ platform powered by HYFT ® technology, ImmunoPrecise is reimagining how biological data can be modeled and deployed at scale. The LENS ai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere. Our integrated framework enables unprecedented zero-shot discovery scenarios where LENS ai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. This unique bio-native AI approach captures functional meaning rather than structural patterns, enabling new capabilities across R&D from drug and vaccine discovery to systems biology and positioning IPA at the frontier of TechBio innovation. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT ® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the Company's strategic direction, the Company's future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in AI and biotechnology; and other risks inherent to the Company's industry and business model. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Business Wire
03-07-2025
- Business
- Business Wire
ImmunoPrecise Validates LENS ai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ('IPA' or the 'Company'), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENS ai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training. LENSai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. 'It's generally assumed that AI can only make accurate predictions if it has seen similar data before,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'But this benchmark proves otherwise: LENS ai accurately mapped antibody binding sites on entirely new antibody - protein complexes-none of which were used in training. Not the antibodies. Not the targets. Not the complexes. And the predictions aligned with wet-lab results. This is a major breakthrough in generalizing AI for therapeutic discovery, made possible by our proprietary technology, which captures functional meaning instead of memorizing shapes. It shows that AI doesn't always need massive data to be powerful and accurate - it just needs the right kind.' LENS ai Epitope Mapping uses artificial intelligence to pinpoint where antibodies are most likely to attach to disease-related proteins - helping scientists design better treatments faster. Unlike traditional methods that take months and require lab work, LENS ai delivers results in hours - using just the digital sequences - cutting timelines, eliminating the need to produce expensive materials, reducing guesswork, and unlocking faster paths to new treatments. In a new benchmark study, LENS ai was tested on 30 antibody-protein pairs, 17 of which the platform had never seen before. Despite having no prior exposure to these molecules, LENS ai achieved prediction scores nearly identical to those from its original training data. This score, known as AUC (Area Under the Curve), is a widely accepted measure of accuracy in computational biology. The consistent performance on entirely new, unseen complexes confirms that LENS ai 's artificial intelligence can reliably analyze and predict antibody binding - even for molecules outside its training set. This breakthrough demonstrates LENS ai 's power to generalize across diverse biological structures, making it a valuable tool for accelerating real-world drug discovery. Why This Benchmark Matters In the new study, LENS ai delivered high accuracy results on 17 antibody-protein complexes the platform had never seen before as it did on familiar training examples - proving true generalization, not memorization. Because no new wet-lab work or x-ray structures were required, researchers gain speed, reproducibility, and major cost savings, while freeing scarce lab resources for confirmatory or downstream assays. What It Means for Partners and Investors With LENS ai already embedded in collaborations across big pharma and biotech, ImmunoPrecise is scaling access through secure APIs and custom partnerships. The platform helps researchers compress discovery timelines, reduce risk, and unlock previously unreachable targets - positioning the company and its investors at the forefront of AI-driven antibody therapeutics. For more technical detail and full benchmark results, explore two complementary case studies that illustrate the power and flexibility of LENS ai Epitope Mapping. The first highlights performance on a 'seen' target, where the system was trained on related data. The second - featured in this press release - demonstrates LENS ai 's breakthrough ability to accurately map binding sites on a completely 'unseen' target, with no prior exposure to the antibody, the antigen, or their structure. These examples underscore how LENS ai performs both in well-characterized systems and in novel, previously untrained scenarios—validating its generalizability and real-world readiness. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the performance, scalability, and broader application of the LENSai™ and HYFT® platforms; the generalizability of the Company's AI models to novel therapeutic targets; the role of AI in accelerating antibody discovery; and the Company's future scientific, commercial, and strategic developments. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological innovation, risks related to model validation and generalizability in real-world settings, intellectual property protection, strategic partner adoption, regulatory pathways, and market demand for AI-driven therapeutic platforms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
Business Wire
24-06-2025
- Business
- Business Wire
ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENS ai™ Platform Powered by Patented HYFT ® Technology
AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also safe, immunologically active, and structurally stable. ImmunoPrecise's patented HYFT technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (DENV-1 through DENV-4). 'This is a major step forward,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'Our AI technology not only found a new target for a universal dengue vaccine, but we've now shown it's safe and can trigger the right immune response. With this validation, we're excited to move ahead and advance this candidate toward the next stages of vaccine development.' Following the recent discovery of a unique 'Achilles' heel' shared by all four types of dengue virus, ImmunoPrecise has confirmed—using its patented HYFT technology and LENS ai Immunogenicity Screener—that the selected target not only remains conserved but also triggers a strong and specific immune response. This breakthrough may pave the way for a safer, more universal dengue vaccine. The new target was discovered using the Company's proprietary LENS ai platform. 'Our ability to move from computational discovery to AI-guided immunogenicity validation is unique to our methodology and drug development,' commented Dr. Jennifer Bath, ImmunoPrecise CEO. 'Further, it ensures that our candidates are both theoretically promising and primed for real-world immune protection, a critical requirement for any viable vaccine candidate.' For decades, dengue has been one of the most challenging viruses for vaccine developers, largely because the virus comes in four different forms—and beating one doesn't guarantee protection from the others. Many vaccines fail because they trigger the immune system to attack the wrong parts of the virus, or worse, make infections more severe. What makes this development so important is that ImmunoPrecise's target has now been shown—based on in silico immune profiling—to likely engage key components of the immune system, including both B cells and T cells, in a manner that appears safe and highly specific. ImmunoPrecise's latest AI-driven testing shows that their selected target—a small, stable piece of the virus—can activate the body's defenses in a very precise way, without the risks of traditional, broader approaches. A Methodology That Changes the Game—Far Beyond Dengue What sets ImmunoPrecise apart is not only the discovery of a promising dengue vaccine target, but the methodology itself. With LENS ai powered by HYFT technology, IPA brings unprecedented clarity to the earliest stages of discovery—well before traditional disease modeling or animal studies even begin. By revealing deep relationships between sequence, structure, and function at the outset, this platform provides rapid, explainable insights that inform every downstream decision, from epitope selection to vaccine design. The findings for dengue showcase the platform's versatility. Because HYFT technology systematically maps biological meaning across the entire biosphere, this methodology is readily transferable—equipping IPA to tackle a wide spectrum of infectious diseases, from HIV and influenza to emerging pathogens and oncology targets. With this approach, ImmunoPrecise isn't just keeping pace with the field; it's setting a new standard for how next-generation therapeutics are discovered and validated. ImmunoPrecise's patented HYFT technology successfully identified a critical and discontiguous target site (epitope) that remains unchanged across all four types of dengue virus (DENV-1 through DENV-4). This target site is essential for how the virus infects cells and is believed to be key for establishing an enduring and efficacious universal dengue vaccine. This HYFT-guided workflow achieves this by analyzing protein building blocks that may be far apart in the virus's genetic sequence but come together when the protein folds into its final 3D shape. This advanced mapping process combines genetic similarity analysis with 3D structural modeling and functional annotation to identify the most promising vaccine targets. Key Technical Findings Complete Immune Response Testing Computer-based immune response screening used advanced prediction tools to evaluate how both antibody-producing cells (B cells) and infection-fighting cells (T cells) would respond to the vaccine target. The target site showed strong predicted binding to multiple human immune system markers (HLA class I and II types). This suggests that people from diverse backgrounds and genetic makeups could mount a strong immune response to the vaccine—something essential for global deployment. Safety Verification Against Human Proteins Using ImmunoPrecise's proprietary retrieve-and-relate technology at the core of HYFT™ (Van Hyfte et al., 2023, bioRxiv), the vaccine target was thoroughly compared against all known human and mouse proteins. This comprehensive safety check goes beyond standard comparison methods—HYFT systematically searches for not only genetic similarities but also structural and functional matches across species, ensuring the vaccine target is unique to the virus and not found in human biology. This is critical in vaccine development, where off-target effects can lead to dangerous autoimmune reactions. No problematic similarities were found, significantly reducing the risk that the vaccine would accidentally attack the body's own healthy cells. Structural Stability Analysis Advanced computer modeling and molecular simulation studies have confirmed that the vaccine target maintains its proper shape, remains accessible to immune cells, and remains prominently displayed on the surface of the dengue virus. Stability testing demonstrated that the target remains robust under normal physiological conditions. Balanced Immune Response Profile Importantly, the moderate predicted immune response strength (compared to typical vaccine 'hotspots') may explain why this target was overlooked in previous laboratory studies that focused on more obvious, highly immunogenic sites. This balanced profile suggests the vaccine could trigger a highly specific immune response while potentially reducing the risk of dangerous immune overreactions or antibody-dependent enhancement (ADE)—a serious complication that can worsen dengue infection. Looking Ahead This release is the second in a series of disclosures aimed at showcasing the power of ImmunoPrecise's end-to-end AI-native platform. The June 5th announcement introduced a promising target; today's release provides the crucial next step: a rigorous validation of that target's safety and immunological relevance. This validation significantly strengthens the translational potential of the candidate, which is currently being prepared for further preclinical evaluation. These findings come at an important time, as global agencies continue to seek safer and more effective dengue vaccines. IPA is actively engaging with key stakeholders to explore the path forward, including potential collaboration, development, and funding partnerships. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the anticipated benefits, scalability, and broader application of the LENSai™ and HYFT® platforms to dengue vaccine development; the advancement, regulatory acceptance, and future clinical potential of AI-native approaches for dengue and other infectious diseases; and the Company's ability to achieve and maintain scientific, regulatory, and commercial progress in its dengue program. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, the pace of scientific and technological developments, changes in regulatory requirements or acceptance of AI designed vaccines, competition and market dynamics, intellectual property protection, risks related to preclinical or clinical validation of dengue vaccine candidates, integration and operational challenges, and changes in global economic or business conditions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
Business Wire
12-06-2025
- Business
- Business Wire
AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence (AI)-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world. The in vitro analysis was conducted by an independent third party, further strengthening the objectivity and reliability of the findings. AI-designed GLP-1 receptor agonist (GLP-1RA) peptide sequences achieve comparable or superior receptor activation to Semaglutide, a benchmark GLP-1 therapy and one of the most commercially successful drugs in the world Share The results validate the power of IPA's LENSai™ platform and its proprietary HYFT™ technology, which enables first-principles-based in silico peptide discovery and optimization. Five rationally engineered peptide sequences—AI-optimized for improved stability and peptidase resistance—were tested against benchmark GLP-1 analogs in receptor activation assays. Two lead candidates outperformed or matched Semaglutide under controlled assay conditions. Crucially, the sequences were not discovered by chance. They were designed using HYFT-derived intrinsic biological patterns—mathematical representations of functional relationships in biology—making this approach highly reproducible and generalizable to other drug targets. With GLP-1 therapies representing one of the fastest-growing segments in the global pharmaceutical market, these results demonstrate that AI can now generate not only predictive but functionally validated peptide drugs, paving the way for rapid expansion into adjacent therapeutic areas using the same HYFT-driven approach. 'This is not a one-off success,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We've demonstrated a scalable, first-principles mechanism to design potent, stable, and biologically active peptide therapeutics. HYFT-guided design unlocks repeatable workflows for other validated targets—whether in cardiometabolic disease, oncology, or infectious disease. It represents a foundational shift in how therapeutics are discovered. The same LENSai-driven approach has already transformed our vaccine and antibody discovery programs, and we are now applying that rinse-and-repeat methodology to metabolic diseases—starting with GLP-1.' IPA is now considering two complementary preclinical paths for its lead GLP-1 candidates: Injectable delivery studies, including pharmacokinetic profiling and efficacy validation in animal models. Non-invasive delivery strategies, including formulation work for transdermal patches and exploratory evaluation of nucleic acid-based delivery, designed to enhance durability, patient compliance, and ease of administration. The sequences were also engineered for compatibility with next-generation expression systems, including nucleic acid-based vectors, which support scalable expression in both traditional and emerging human-relevant models, aligning with evolving regulatory interest in more predictive, flexible, and efficient therapeutic development approaches. The significance of this breakthrough extends far beyond GLP-1. The same AI framework and HYFT-driven approach that generated these potent peptide drugs can now be applied to other high-value therapeutic targets—quickly, efficiently, and with built-in biological relevance. This announcement follows IPA's recent success with AI-designed dengue virus vaccine candidates, reinforcing the broad applicability of its technology across both infectious and non-infectious diseases. About ImmunoPrecise Antibodies Ltd. ImmunoPrecise (NASDAQ: IPA) is a global leader in AI-powered biotherapeutic discovery and development. Its proprietary HYFT™ technology and LENSai™ platform enable first-principles-based drug design, delivering validated therapeutic candidates across modalities and therapeutic areas. IPA partners with 19 of the top 20 pharmaceutical companies and is advancing next-generation biologics through data-driven, human-relevant models. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, those related to the anticipated benefits, scalability, translatability, adoption, and broader application of the LENSai™ and HYFT® platforms; the advancement and regulatory acceptance of AI-native drug discovery methods; the continued development and potential preclinical or clinical progression of IPA's AI-designed GLP-1 peptide program; the feasibility of next-generation delivery strategies; and the Company's ongoing ability to maintain scientific, regulatory, and commercial momentum in this and related therapeutic areas. Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. Such factors include, but are not limited to, scientific or technological developments, changes in regulatory requirements or acceptance of AI-designed therapeutics, competitive or market dynamics, intellectual property protection and enforcement, risks related to preclinical or clinical validation, integration or operational risks, and changes in economic or business conditions. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the year ended April 30, 2024 (available on the Company's SEDAR+ profile at and EDGAR profile at Should any of these risks materialize, actual results could vary significantly from those currently anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise forward-looking statements to reflect subsequent events or circumstances.
